HSV-NT3 Vector for Chemotherapy-Induced Peripheral Neuropathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of cancer treatment that current treatments only partially address, with existing methods showing inconsistent success in managing symptoms and preventing nerve damage.
Innovation Solution
A herpes simplex virus (HSV) McKrae strain variant engineered to express neurotrophin 3 (NT3) is used, delivered via a viral vector that targets the dorsal root ganglia to provide prophylactic and therapeutic treatment, allowing for the prevention, inhibition, or reversal of neuropathy, enabling higher chemotherapy doses and longer treatment durations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is administered to treat cancer, then cancer treatment efficacy is improved, but chemotherapy-induced peripheral neuropathy (CIPN) occurs as a side effect
Solution Approach 1:
The patent utilizes the HSV virus's natural tropism for neuronal cells and its ability to establish lifelong latency in the nervous system. By engineering the virus to express NT3 (a neuroprotective factor) instead of replicating, the harmful viral properties are converted into therapeutic benefit. The virus delivers neuroprotection precisely to the affected dorsal root ganglia where chemotherapy damage occurs, transforming a potential pathogen into a targeted delivery vehicle for neuropathy prevention and treatment.
Solution Approach 2:
The HSV-NT3 vector serves as an intermediary between the chemotherapy treatment and the nervous system. It mediates protection by delivering NT3 directly to dorsal root ganglia, bridging the gap between systemic chemotherapy administration and localized neuroprotection. This intermediary approach allows high-dose chemotherapy to be administered while the vector simultaneously protects neural tissues from damage.
2Reliability
If higher chemotherapy doses are administered to improve treatment outcomes, then cancer treatment effectiveness increases, but neuropathy severity increases
Solution Approach 1:
The HSV-NT3 vector is administered before chemotherapy treatment begins, establishing neuroprotection in advance. The virus infects dorsal root ganglia and begins expressing NT3 prior to chemotherapy exposure, creating a protective environment that prevents neuropathy even when high-dose chemotherapy is subsequently administered. This preliminary action allows aggressive cancer regimens to proceed without neuropathy limitations.
Solution Approach 2:
The invention changes the biochemical parameters within dorsal root ganglia by introducing NT3 expression. This alters the neurotrophic environment from one vulnerable to chemotherapy damage to one that is protected and supportive of neuronal survival. The parameter change in NT3 concentration enables tolerance to higher chemotherapy doses that would otherwise cause severe neuropathy.
3Ease of operation
If existing neuropathy treatment methods are used, then some symptom relief is achieved, but treatment success is inconsistent and limited
Solution Approach 1:
The HSV-NT3 vector establishes self-sustaining neuroprotection that does not require repeated administrations or external intervention. Once the virus infects dorsal root ganglia, it maintains lifelong latency while continuously providing NT3 expression and neuroprotective effects. This self-service mechanism eliminates the inconsistency of current treatments that require frequent monitoring and adjustment, providing reliable, long-term protection.
Solution Approach 2:
The vector provides continuous neuroprotection throughout the patient's life, unlike current treatments that are intermittent and short-term. The HSV maintains persistent latency in dorsal root ganglia, ensuring uninterrupted NT3 expression and ongoing protection against neuropathy. This continuity transforms neuropathy management from a series of discrete symptomatic interventions to a sustained protective therapy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed herein are compositions and methods for treating neuropathy, embodiments, HSV vectors are provided comprising nucleic acid molecules encoding neurotrophins, such as neurotrophin 3 (NT3).